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Abstract
Background: Nightly extended hours hemodialysis may improve left ventricular hypertrophy and function and
endothelial function but presents problems of sustainability and increased cost. The effect of alternate nightly
home hemodialysis (NHD) on cardiovascular structure and function is not known.
Methods: Sixty-three patients on standard hemodialysis (SHD: 3.5-6 hours/session, 3-5 sessions weekly) converted
to NHD (6-10 hours/session overnight for 3-5 sessions weekly). 2Dimensional transthoracic echocardiography and
ultrasound measures of brachial artery reactivity (BAR), carotid intima-media thickness (CIMT), total arterial
compliance (TAC) and augmentation index (AIX) were performed post dialysis at baseline and 18-24 months
following conversion to NHD. In 37 patients, indices of oxidative stress: plasma malonyldialdehyde (MDA) and anti-
oxidant enzymes: catalase (CAT), glutathione peroxidase (GPX) and superoxide dismutase (SOD) activity and total
antioxidant status (TAS) were measured at baseline, 3 and 6 months.
Results: Left ventricular mass index (LVMI) remained stable. Despite significant derangement at baseline, there
were no changes in diastolic function measures, CIMT, BAR and TAC. AIX increased. Conversion to NHD improved
bone mineral metabolism parameters and blood pressure control. Interdialytic weight gains increased. No definite
improvements in measures of oxidative stress were demonstrated.
Conclusions: Despite improvement in uremic toxin levels and some cardiovascular risk factors, conversion to an
alternate nightly NHD regimen did not improve cardiovascular structure and function. Continuing suboptimal
control of uremic toxins and interdialytic weight gains may be a possible explanation. This study adds to the
increasing uncertainty about the nature of improvement in cardiovascular parameters with conversion to intensive
hemodialysis regimens. Future randomized controlled trials will be important to determine whether increases in
dialysis session duration, frequency or both are most beneficial for improving cardiovascular disease whilst
minimizing costs and the impact of dialysis on quality of life.
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Cardiovascular disease is a leading cause of morbidity
and mortality, accounting for approximately 30-40% of
deaths in end stage kidney disease (ESKD) patients [1].
Left ventricular hypertrophy (LVH), dilatation and sys-
tolic and diastolic dysfunction are common and inde-
pendently associated with mortality [2,3]. These
changes are postulated to result from chronic volume
overload (due to salt and water retention, chronic ane-
mia and arteriovenous fistulae), pressure overload (due
to hypertension, atherosclerosis, vascular and cardiac
valvular calcification), metabolic (acidosis, malnutri-
tion, inflammation and oxidative stress) and neuroen-
docrine factors (renin-angiotensin-aldosterone and
sympathetic activation) [4,5].
Vascular disease occurs in two main forms: 1) arterio-
sclerosis with diffuse arterial wall dilatation, thickening,
fibrosis and calcification resulting in stiffening and 2)
atherosclerosis with abnormal endothelial function and
patchy intimal plaques, causing abnormal regulation of
vascular tone, fibrinolysis and smooth muscle prolifera-
tion with narrowing or obstruction of the arterial
lumen. Increasing arterial stiffness raises pulse wave
amplitude and velocity, causing reflected pressure waves
from the periphery to be stronger and to arrive in the
ascending aorta in systole rather than diastole, thus
increasing systolic blood pressure and decreasing diasto-
lic blood pressure. The resulting increased pressure load
on the left ventricle (LV) during systole promotes LV
hypertrophy and the reduced pressure in diastole
reduces coronary artery perfusion, promoting myocar-
dial ischemia [6,7]
Traditional risk factors for CV disease are more pre-
valent in ESKD patients compared to the general
population. When adjusted for age, gender and race,
ESKD patients have a higher prevalence of diabetes,
hypertension, physical inactivity, hypertriglyceridemia
and reduced high density lipoprotein [8]. However, tra-
ditional risk factors explain only approximately half the
all cause mortality and variation in CV mortality in
ESKD [9]. Other novel risk factors including inflamma-
tion, malnutrition, anemia, vascular calcification sec-
ondary to deranged bone mineral metabolism (BMM),
oxidative stress and hyperhomocysteinemia have been
associated with adverse CV outcomes in ESKD [10,11].
The exact role of these novel risk factors as surrogate
markers of CV disease and mortality in ESKD remains
controversial.
Daily nocturnal hemodialysis (6-7 nights weekly, 8-10
hours/session) has been associated in observational stu-
dies [12-18] and 1 randomized controlled trial [19], with
significant, sustained improvement in surrogate markers
of mortality including BMM indices, blood pressure, LV
ejection fraction and mass, homocysteine, serum
albumin and hemoglobin. One group has shown
improvement in BAR and arterial compliance [20-22]
Alternate nightly hemodialysis(NHD) may reduce the
burden and financial cost of dialysis compared with
daily regimens, however, its effects on cardiovascular
parameters are undefined. We sought to compare cardi-
ovascular responses and cardiovascular risk factor pro-
files in standard duration hemodialysis (SHD) and
alternate nightly NHD regimens, and to identify the cor-
relates of these changes.
Methods
Study Population and Design
The study followed a prospective cohort design per-
formed at a single centre. Between 2003 and 2006, con-
senting adults (≥ 18 years) with ESKD, established on
home hemodialysis for ≥ 3 months were converted from
a 3.5-6 hours/session, 3-5 sessions weekly home hemo-
dialysis regimen to home NHD (6-10 hours overnight/
session for 3-5 sessions weekly). Within the range of 3-5
sessions weekly and 6-10 hours/session, patients tailored
their dialysis regimen to suit their lifestyle and sleeping
habits. Interdialytic intervals of greater than 2 days were
discouraged. Changes to the dialysis prescription are
outlined in Tables 1 and 2
A diet low in saturated fat, salt and sugar with a daily
protein intake of 1.2-1.4 g/kg dry weight/day and fluid
restriction to maintain interdialytic weight gains < 3 kg
was recommended. Dietary phosphate and potassium
restrictions were relaxed upon commencement of NHD.
Phosphate binders were ceased at the time of conversion
to NHD and reintroduced only as required to maintain
predialysis serum phosphate < 1.6 mmol/L. At baseline,
calcitriol
® (1,25 OH2 V i tD )w a so n l yc o n t i n u e di n
patients in whom it was required to maintain serum cal-
cium in the normal range post previous parathyroidect-
omy or in those with severe hyperparathyroidism (PTH
Table 1 Demographic and Baseline Clinical Data
Clinical Variable NHD (n = 63)
Age (Years) 51.5 ± 13
% Male 79
Body Mass Index(kg/m
2) 28.9 ± 7.6
Dialysis Duration (%) < 2 years 56
2-5 years 25
> 5 years 19
Previous Renal Transplant(%) 22
Smoking Status (%) Never 46
Former 48
Current 6
Clinically Apparent Cardiovascular Disease(%) 25
Diabetes (%) 33
NHD = Nocturnal hemodialysis
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Page 2 of 15> 8 times the upper limit of normal). Vitamin D supple-
ments were reintroduced as necessary to maintain pre-
dialysis serum calcium levels in the normal range and
parathyroid hormone levels 2-6 times the upper limit of
the normal range where possible. All patients were pre-
scribed folic acid 5 mg daily, Multi B Forte
® 1t a b l e t
daily (Thiamine 7.27 mg, Riboflavin 6 mg, Nicotinamide
45 mg, pyridoxine 0.7 mg and ascorbic acid 45 mg) and
pyridoxine 25 mg daily as oral supplements. The proto-
col for conversion to NHD was approved by the Prin-
cess Alexandra Hospital Human Research Ethics
Committee.
Outcome measures
Cardiovascular structure and function studies were sched-
uled to be performed at baseline, 6, 12, 18 and 24 months
following conversion to NHD. Cardiac and vascular stu-
dies at each time point were performed at the same visit.
Images were collected post-dialysis and interpreted by
experienced staff, blinded to patients’ clinical information.
Echocardiographic Assessment
Left ventricular volumes, mass, systolic function, diasto-
lic function and filling pressures were assessed using 2
Dimensional echocardiography. Left ventricular (LV)
end diastolic (EDV) and end systolic volumes (ESV)
were calculated using the Modified Simpson’sR u l e .L V
mass was calculated using the Devereux method [23].
Left ventricular mass index (LVMI) was calculated by
indexing LVMass to Height
2.7, which is a better predic-
tor of mortality in dialysis patients compared to LVmass
indexed to body surface area (BSA) [24]. LVMI cor-
rected to body surface area (Dubois and Dubois Method
[25]) is also reported.
Diastolic function was assessed using peak early mitral
inflow filling velocity (E), peak mitral filling velocity at
atrial contraction (A), E/A, deceleration time of the
mitral E wave (DT) and tissue doppler velocity of the
mitral annulus (E
l)[26]. LV filling pressures were
assessed using the E/E
l ratio and left atrial volume
(LAVol), calculated using the Modified Simpson’sR u l e .
Table 2 Dialysis Prescription 1
Variable Baseline Nocturnal Haemodialysis
Frequency (sessions/week) 3: 9.5% 3: 4.8%
3.5: 47.6% 3.5: 69.4%
4: 39.7% 4: 24.2%
5: 3.2% 5: 1.6%
Median (Interquartile Range) 3.5 (3-4) (3.5 (3.5-4)
Duration (Hours/Session) < 4: 6.3% 6-7.5: 9.7%
4: 14.3% 8: 9.7%
4.5: 12.7% 8.5: 14.5%
5: 41.3% 9: 51.6%
5-6: 25.3% 9-11: 14.5%
Median (Interquartile Range) 5 (3.5-5) 9 (7-10)
Membrane Type
Surface Area (m
2)
Polysulfone Polysulfone
1.4: 1.6% 1.4: 16.1%
1.7: 52.4% 1.7: 56.5%
2.1: 46.0% 2.1 27.4%
Median (Interquartile Range) 1.7 (1.7-2.1) 1.7 (1.4-2.1)
Flux High: 95.2% High: 100%
Blood Flow Rate (mL/min) 200-230: 3.2% 200-230: 43.5%
240-275: 27.0% 240-275: 53.2%
280-325: 49.2% 280-325: 3.3%
330-360: 20.6% 330-360:
Median (Interquartile Range) 275 (250-350) 250 (200-275)
Dialysate Flow Rate (mL/min) 300: 20.6%
500: 100% 500: 79.4%
Cannulation Technique Self Cannulating: 76.2% Self Cannulating: 76.2%
Dual Needle (14/15 guage) Dual Needle (14/15 guage)
AVF: 90.5% Buttonhole AVF: 93.7% Buttonhole
AVG: 100% Rope Ladder AVG: 100% Rope Ladder
NHD = Nocturnal hemodialysis
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Page 3 of 15LAvol index (LAVolI) was calculated by indexing LaVol
to BSA (Dubois and Dubois Method). The categorical
definition of diastolic dysfunction was that outlined by
Omen and Nishimura [26].
Vascular Structure and Function Studies
Brachial Artery Reactivity (BAR), a measure of endothe-
lial function, was calculated as percentage change in
brachial artery diameter, measured using high resolution
B mode ultrasonography, with the induction of reactive
hyperemia induced by arterial occlusion for 4.5 minutes,
using a sphygmomanometer cuff [27,28]. BAR in healthy
populations has been reported to range from 0.2 to
19.2% [29]. Endothelial dysfunction measured by these
methods has been shown to correlate with the extent
and severity of coronary artery disease determined by
angiography [30].
Carotid intima-media thickness (CIMT), a measure of
arterial wall thickness, was determined by averaging 3
measurements taken on each carotid artery (anteriorly,
laterally and posteriorly) measuring the distance
between the leading edge of the lumen-intima interface
and the leading edge of the collagenous upper layer of
the adventitia using high resolution B mode ultrasono-
graphy. Measures were taken in areas free of obvious
atherosclerotic plaque around the level of the carotid
b i f u r c a t i o n .C I M Ti sam a r k e rf o rt h ep r e s e n c ea n d
severity of arteriosclerosis and has been associated with
risk factors for cardiovascular disease, all cause and car-
diovascular mortality [31-33] A systematic review has
shown an increased risk of myocardial infarction with
CIMT > 0.822 mm and an increased risk of stroke with
C I M T>0 . 7 5m m[ 3 4 ] .O u rg r o u ph a ss h o w ni n c r e a s e d
cardiovascular and all-cause mortality is associated with
CIMT > 0.62 mm [35].
Total arterial compliance (TAC), a measure of arterial
stiffness, was calculated using the pulse-pressure method
[36,37]. Applanation tonometry (Millar SPT-301 Mikro-
Tip transducer, Millar Instruments, Houston, TX), was
performed on the left radial artery. BP was measured in
the right arm, using a sphygmomanometer, with the
patient resting supine for 10 minutes. The radial tono-
metric waveform was calibrated by assuming equiva-
lence of mean [(2*Diastolic BP + Systolic BP)/3] and
diastolic brachial cuff pressure. The radial tonometric
waveforms were obtained simultaneously with pulsed-
wave Doppler, digitized (WaveBook 512, IOTech Inc.,
Cleveland, OH), and transferred to a computer, where
they were synchronized using the R wave of the electro-
cardiogram. Using specialized acquisition software, ECG
gated data using tonometry and Doppler were acquired.
Echocardiographic images and pulsed Doppler were
acquired using a standard ultrasound system with 3.5
MHz and 11 MHz harmonic imaging probes. Stroke
volume was derived from the pulsed Doppler and LV
outflow tract dimensions [38]. The tonometric wave-
forms and aortic outflow data were analysed using a cus-
tom written program. Up to 10 cardiac cycles were
averaged and central pressure was derived by applying a
generalized transfer function to the radial tonometric
pressure data [39] Values for TAC were then derived
using the iterative method described by Stergioupulos
[40]. Our group has previously documented TAC in nor-
mal subjects of 1.32 ± 0.58 mL/mmHg([41]. Our group
has also shown TAC < 0.94 mL/mmHg is associated with
mortality and the composite endpoint of death and hos-
pital admissions for cardiovascular causes [42].
Augmentation Index (AIX), which reflects cardiac
stroke volume and the effects of vascular stiffness, was
calculated using the formula: AIX = augmentation pres-
sure/pulse pressure)*100, where augmentation pressure
= systolic blood pressure -pressure at the first inflection
point on the central pressure wave form which was gen-
erated using a validated generalized transfer function
from recordings of the radial artery pulse using applana-
tion tonometry (SphygmoCor 7.01; AtCor Medical) and
pulse pressure = systolic-diastolic blood pressure
[43,44]. Previously published studies have measured a
central AIX in normal populations of 30-45% [45].
Cardiovascular Risk Factors and Prescribed Medications
Interdialytic weight gains were calculated from pre and
post dialysis total body weights measured by patients on
bathroom scales. BP was recorded pre- and post-dialysis
by patients using digital sphygmomanometers. Serum or
plasma levels of lipids, hemoglobin, C reactive protein
(CRP), albumin, parathyroid hormone (PTH), calcium,
phosphate and homocysteine were measured using stan-
dard laboratory techniques on blood samples taken pre-
dialysis in the fasting state. Measures of oxidative stress
including, plasma malonyldialdehyde (MDA) and red
blood cell (RBC) anti-oxidant enzymes catalase (CAT),
glutathione peroxidase (GPX) and superoxide dismutase
(SOD) activity, and plasma GPX activity and total anti-
oxidant status (TAS) were measured pre and post dialy-
sis at baseline and 3 and 6 months after conversion to
NHD, in the last 37 patients recruited to the study.
MDA was measured using high performance liquid
chromatography. Activities of CAT, GPX and SOD and
TAS were measured using standard spectrophotometric
methods. Prescribed medications were determined by
review of the medical record and patient interview.
Statistical methods
Statistical analyses were performed using STATA SE
version 10.0. Sample size calculations indicated that 21
patients were required to have 80% power of detecting a
30% decrease in LVMass, allowing for 33% drop-out
rate. Fifteen patients were required to have 80% power
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0.05 mm change in CIMT and 13 patients to detect a
0.4 unit change in TAC with conversion to NHD.
Variables are expressed as percentages for categorical
data and, for continuous data, as mean ± standard devia-
tion if normally distributed and median (interquartile
range) if skewed. Longitudinal analysis was performed
using paired t-test if normally distributed and Wilcoxon
signed rank test if skewed. Univariable and multivariable
linear regression analyses were performed to assess cor-
relations between changes in cardiovascular parameters
and risk factors. The covariates considered for inclusion
in the model included age, gender, duration of renal
replacement therapy, diabetes and changes in lipids, sys-
tolic and diastolic blood pressure, interdialytic weight
gains, parathyroid hormone, phosphate and calcium,
hemoglobin, ferritin and transferrin saturation, C reactive
protein and albumin. Those with a p < 0.25 on univari-
able analysis were introduced into a multivariable model.
Then a stepwise, backward elimination process was per-
formed, removing variables which contributed least sig-
nificantly to the model provided they did not change the
incident rate ratio by more than approximately 10%.
For correlation analyses, results are reported as the
point estimate, b and 95% confidence intervals (CI), the
correlation coefficient (r) and p value. P value < 0.05
was considered significant a priori.
Results
Demographic Data and Dialysis Prescription
Eighty-seven percent of the eligible home hemodialy-
sis population agreed to participate in the study.
Demographic and dialysis prescription data are pre-
sented in Tables 1 and 3. Median kt/V urea was 1.3
(1.1-1.5) on conventional hemodialysis and 1.5 (1.3-
1.9) on NHD.
Four patients died (Followed on NHD for 2, 5, 12
and 17 months)), 10 received renal transplants (Fol-
l o w e do nN H Df o r7 . 5[ 6 - 1 7 ]m o n t h s )a n d7w i t h d r e w
consent to participate in the study (Followed on NHD
for: 9 [2-13] months) during the 24 months follow up.
The other patients without paired data for analysis
failed to attend for investigations without withdrawing
from the study.
Follow-up cardiac and vascular studies were per-
formed at 18 (12-24) months. The timing of follow up
investigations was determined by patient attendance at
echocardiograms that were scheduled to occur 6
monthly between baseline and 24 months following con-
version to NHD. The majority of patients only attended
for 2 echocardiograms. The study performed at the lat-
est time point during the 24 month follow up was uti-
lized for analysis. Paired data was available for
echocardiographic parameters in 38 patients, CIMT and
BAR in 42 patients and TAC and AIX in 28 patients.
LV Structure and Function
Measures of LV structure and systolic function did not
change between baseline and follow up. (Table 4 and
Figure 1) At baseline, 64% of patients had LVMI within
the normal range. Of the 40 patients with paired data,
93% maintained LVMI within 30% of baseline measure-
ment and only 7% had a ≥ 30% increase in LVMI. In
the subset of patients with abnormal LVMI at baseline,
Table 3 Dialysis Prescription 2
Variable Baseline Nocturnal Haemodialysis
Dialysate Calcium (mmol/L) 0.9-1.0: 17.5%
1.25-1.3: 77.8% 1.25-1.3: 1.6%
1.5-1.6: 4.7% 1.5-1.6: 90.3%
1.75: 1.75: 8.1%
Median (Interquartile Range) 1.3 (1.0-1.3) 1.5 (1.5-1.75)
Dialysate Potassium (mmol/L) 1-1.25: 19.0% 1-1.25: 32.3%
1.5: 47.7% 1.5: 21.0%
2.0-2.5: 27.0% 2.0-2.5: 43.5%
3: 6.3% 3: 3.2%
Median (Interquartile Range) 1.5 (1.25-3) 1.5 (1-2.5)
Dialysate Bicarbonate (mmol/L) 28-30: 16.1%
32: 3.2% 32: 83.9%
35: 96.8%
Dialysate Sodium (mmol/L) 140: 100% 140: 100%
Dialysate Magnesium (mmol/L) 0.5: 100% 0.5: 100%
Dialysate Glucose (mmol/L) 5: 100% 5: 100%
Dialysate Phosphate 0: 100% 30.6% added phosphate in the form of fleet 0-40 mL
NHD = Nocturnal hemodialysis
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Page 5 of 15there was no change in LVMI over time (n = 14, 57 ± 6
vs 61 ± 10 g/m
2.7).
Measures of diastolic function and filling pressure
remained stable (Table 4). Diastolic dysfunction was
present in 74% of patients at baseline and 70% at follow
up. The most common abnormality was raised LAVol.
Vascular Structure and Function
BAR did not change between baseline and follow-up.
(Figure 2): 2.82 (1.12-6.3) vs 3.48 (1.68-7.95)%, p = 0.47.
CIMT did not change between baseline and follow-up.
(Figure 3): 0.66 ± 0.14 mm vs 0.65 ± 0.16 mm, p = 0.26.
There was no significant change in TAC between base-
line and follow-up: 1.4 (1.1-1.7) vs 1.3 (1.0-1.6)mL/
mmHg, p = 0.86 (Figures 4). AIX increased from 21 (14-
35)% to 27 (17-36)%, p = 0.025 (Figure 5). There was no
significant change in pulse pressure between baseline and
follow up: 66 (50-75) vs 60(50-73)mmHg, p = 0.46.
Cardiovascular Risk Factors
Changes in cardiovascular risk factors are presented in
Table 5. There was significant improvement in predialy-
sis diastolic BP. There was a trend toward improvement
in predialysis systolic BP. Interdialytic weight gains
increased: 2.3 ± 0.8 vs 2.7 ± 1.0 kg, p = 0.006. Antihy-
pertensive medication doses were stable or reduced in
the majority (57% dose stable, 34% reduced, 9%
increased). The percentage of patients being prescribed
no antihypertensive medications increased from 47% to
66%, p = 0.03. Seven patients ceased an ACE inhibitor
or angiotensin receptor blocker and 5 ceased a b
blocker. One patient newly commenced an ACE inhibi-
tor. HMG CoA reductase inhibitors were prescribed to
51% of patients at baseline. The dose was stable (65%)
or reduced (3%) in the majority of patients and only 8%
of patients newly commenced HMG CoA reductase
inhibitor medications during the study. Hemoglobin and
iron stores remained stable. Weekly darbepoietin alpha
dose decreased (p = 0.007). Weekly intravenous iron
dose remained stable.
There was significant improvement in predialysis
serum phosphate, calcium-phosphate product and para-
thyroid hormone levels (PTH). Serum predialysis cor-
rected calcium levels rose. By 12 months following
conversion to NHD, seventy-three percent of patients
had predialysis serum phosphate levels ≤ 1.6 mmol/L.
This was achieved despite a substantial decrease in
requirement for phosphate binding medications (calcium
carbonate, aluminium hydroxide and magnesium trisili-
cate). Only 6% of patients were not taking any phos-
phate binders at baseline and this increased to 79% on
NHD. Calcium carbonate was prescribed to 90% of
patients at baseline at an average dose of 2460 mg per
day. On NHD, only 15% of patients were prescribed cal-
cium carbonate at an average dose of 1670 mg/day.
Addition of phosphate to the acid component of the
dialysate on NHD was required in 29% of patients at an
average dose of 20 ml of Fleet/10 L (Fleet contains
sodium phosphate monobasic 19 g and sodium phos-
phate dibasic 7 g per 118 mL and sodium content = 4.4
g/118 mL). Parathyroid hormone levels fell significantly
from an average baseline of 290 (140-471) to 160 (62-
290) ng/L; p = 0.03. Fifty-eight percent of patients were
prescribed calcitriol at baseline in an average dose of 1.4
mcg/week. After 12 months on NHD, 53% were pre-
scribed calcitriol at an average dose of 1.8 mcg/week.
There was no significant change in predialysis plasma
M D A .T h ei n c r e a s ei nM D Ao b s e r v e dd u r i n gd i a l y s i s
Table 4 Change in Left Ventricular Structure and Systolic and Diastolic Function with Conversion from SHD to NHD
Variable Baseline on SHD Follow up on NHD Comparison (Δ (95% CI), p value)
(n = 38)
EDV (mL)
(Normal Mean: Men 111 mL, Women 80 mL)
114 ± 28 112 ± 40 -4.37 (-14.01 to 5.27) p = 0.4
ESV (mL)
(Normal Mean: Men 34 mL, Women 29 mL)
47 ± 14 50 ± 26 0.98 (-4.28 to 6.23) p = 0.7
LVEF (%)
(Normal > 50%)
59 ± 6 57 ± 8 1.71 (-4.28 to 3.95) p = 0.1
LVMI (g/m2.7) (Cut off for LVH: men 50, Women 47 g/m2.7) 47 ± 10 49 ± 12 2.34 (-0.08 to 4.76) p = 0.06
Early Transmitral Flow Velocity (m/s)
(Normal 0.6-0.8 m/s)
0.80 ± 0.25 0.79 ± 0.28 -0.005 (-0.08 to 0.07) p = 0.88
E/A Ratio (Normal < 0.75) 1.0 ± 0.49 1.06 ± 0.37 0.02 (-0.12 to 0.16) p = 0.77
Deceleration Time (ms) (Normal > 240 ms) 227 ± 57 213 ± 48 -14.10 (-28.79 to 0.61) p = 0.06
Annular Tissue Doppler Velocity (cm/s) (Normal > 10 cm/s) 5.88 ± 1.72 5.73 ± 1.85 -0.15 (-0.81 to -.52) p = 0.66
E/Ei (Normal < 8) 14 ± 4 15 ± 7 0.01 (-0.008 to 0.028) p = 0.28
Left Atrial Volume Index (mL/m
2) (Normal Median 21 mL/m
2) 40 ± 12 40 ± 12 -0.45 (-4.16 to 3.26) p = 0.81
SHD = Standard hours hemodialysis; NHD = Nocturnal hemodialysis; EDV = Left ventricular end diastolic volume; ESV = Left ventricular end systolic volume; LVEF
= Left ventricular ejection fraction; LVMI = Left ventricular mass index; EA = Peak early mitral inflow filling velocity; A = peak mitral filling velocity at atrial
contraction; E
l = Tissue Doppler velocity of the mitral annulus; CI = confidence interval
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RBC-CAT activity significantly increased between base-
line and 6 months and change during dialysis remained
stable. Predialysis RBC-GPX activity decreased and there
was no change during dialysis. Plasma GPX activity
increased marginally pre dialysis and had a greater
increase during dialysis at 3 months. This was not sus-
tained at 6 months. RBC-SOD and plasma TAS levels
predialysis and change in these levels with dialysis
remained stable (Table 6).
There were no strong associations between change in
cardiovascular outcome measures and cardiovascular
risk factors measured in this study. There were no sig-
nificant associations on univariable or multivariable ana-
lysis with change in LVMI. Changes in diastolic
parameters were associated on multivariable analysis
with changes in markers of inflammation and nutrition,
iron stores and PTH: early transmitral flow velocity and
CRP: 0.008 (0.00001- 0.18), p = 0.05, R
2 = 0.48, E/A
Ratio and CRP: 0.019 (0.003-0.04), p = 0.02, R
2 = 0.36,
E/E
I and CRP: 0.003 (0.0005-0.005), p = 0.02, R
2 =0 . 3 5
and E/E
I and Albumin: 0.006 (0.001-0.011), p = 0.02,
R
20.35, early transmitral flow velocity and transferrin
saturation: -0.008 (-0.13 to -0.003), p = 0.005, R
2 = 0.48,
E/A ratio and transferrin saturation: -0.012 (-0.022 to
-0.003) p = 0.01, R
20.36, deceleration time and ferritin:
0.08 (0.02-0.13), p = 0.01 R
2 = 0.49, early transmitral
flow velocity and PTH: -0.0003 (-0.0006 to-4.01e
-6), p =
0.05, R
2 = 0.48 and deceleration time and PTH: 0.05
(0.004-0.10), p = 0.02, R
2 = 0.49). LaVol Index was asso-
ciated with interdialytic weight gain (9.47 (3.29-15.64), p
= 0.004, R
20.45) on multivariable analysis.
Change in BAR was associated on multivariable analy-
sis with age (-0.14 (-0.27 to -0.006), p = 0.04, R
2 = 0.32).
Change in CIMT was associated on multivariable analy-
sis with change in predialysis serum phosphate (0.34
(0.043-0.065), p = 0.03 and CRP (-0.002 (-0.004 to
-0.003), p = 0.03, R
2 = 0.24). Change in AIX was asso-
ciated on multivariable analysis with change in triglycer-
ides (0.03 (0.001-0.06, p = 0.04 and CRP (0.01 (0.004-
0.02), p = 0.003, R
2 = 0.52).
Discussion
In this study, conversion from conventional home HD
to alternate nightly home NHD had no significant
effects on cardiovascular structure and function indices,
after a mean follow-up of 18 months, despite favorable
changes in recognized cardiovascular risk factors.
0
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0
Baseline Follow Up
n=38
p=0.06
Figure 1 Change in Left Ventricular Mass Index with Conversion to NHD. NHD = Nocturnal hemodialysis.
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Page 7 of 15Previous studies examining the effects of using
increased intensity dialysis or renal transplantation
(RTx) to improve the uremic milieu, on cardiovascular
structure and function have come to inconsistent con-
clusions. Some studies, including 1 randomized con-
trolled trial (Culleton et al) have shown improvement
in LV geometry with conversion to daily hemodialysis
regimens (15, 17, 18, 19). The Frequent Hemodialysis
Trial Group recently published important data from 2
randomized controlled trials. The first compared
LVmass, measured by cardiac magnetic resonance ima-
ging (MRI), in 125 patients managed with short daily
hemodialysis with 120 patients managed on conven-
tional thrice weekly hemodialysis [46]. Short daily
hemodialysis resulted in a significant improvement in
LV mass of 16.4+/-2.9 g compared to 2.6+/-3.2 g in
the conventional hemodialysis group. In contrast, the
second study compared LVmass, measured by cardiac
MRI, in 87 patients randomized to either a daily noc-
turnal hemodialysis or a conventional thrice weekly
hemodialysis regimen. This study showed no signifi-
cant improvement in the primary outcome of death/
LVmass composite [47]. Patel et al, found no
improvement in LVMI 2.5 years after renal transplan-
tation using cardiac MRI [48]
This study is the first to explore the effect of an
extended hours hemodialysis regimen on cardiac diasto-
lic function and no improvement was shown. Studies in
renal transplantation, the gold standard for management
of ESKD, have also consistently reported no improve-
ment in diastolic dysfunction [49,50]. This may suggest
that diastolic dysfunction associated with uremia may
not be substantially reversible, even with correction of
uremia and volume overload.
Chan et al reported significant improvement in BAR
from -2.7 ± 1.8% to 8.0 ± 1.0% in 18 patients and TAC
from 0.98 ± 0.13 to 1.43 ± 0.2 mL/mmHg in only 10
patients, 2 months following conversion to daily NHD.
They have explored possible pathologic mechanisms
driving this improvement and found increased barore-
flex sensitivity for heart rate and proliferation and
migration of endothelial and vascular smooth muscle
cells with normalization of markers of vascular smooth
muscle cell biology including caspase-3 and RunX-2
[20-22,51]. Several published studies show improvement,
of approximately 1-4%, in endothelial function following
0
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0
Baseline Follow Up
p=0.47
n=42
Figure 2 Change in Brachial Artery Reactivity with Conversion to NHD. NHD = Nocturnal hemodialysis.
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Page 8 of 15renal transplantation using both non-invasive techni-
ques, similar to those used in our study [52-55], and
invasive techniques [56] at 2 weeks (n = 30), 1-3 months
(n = 58, 27 and 42) and 12-24 months (n = 8). Studies
examining the effect of RTx on CIMT reached inconsis-
tent conclusions with some demonstrating improvement
[55,57,58] (n = 42, 22 and 19, Follow-up = 3, 12 and 40
months) whilst others showed no improvement [59-61]
(n = 36, 9 and 26, Follow-up: 12 and 6 months). Some
[59,62] (n = 36 and 20, Follow-up = 12 and 3 months),
although not all [63] (n = 36, Follow up = 3 months),
studies have shown improvement in measures of arterial
stiffness such as pulse wave velocity and AIX with RTx.
AIX improved by approximately 10%.
One possible explanation for our findings is that
patients in our study had lower baseline LVMI and less
derangement of baseline BAR and TAC compared to
patients in other quotidian hemodialysis studies where
improvements were shown. Baseline LVMI indexed to
BSA in our study was 106 ± 24 g/m
2, appreciably lower
than the baseline measurements reported by Ayus et al
(154 ± 33 g/m
2), Chan et al (180 ± 54 g/m
2 and 147 ±
42 g/m
2) and Culleton et al (177.4 ± 51.1 g/m
2)
[14,17,19]. Some of these studies pre-selected patients
with cardiovascular dysfunction for entry and were
uncontrolled in design. Notably, our baseline dialysis
schedule (3-5 sessions weekly, 3.5-6 hours/session) was
more intensive than the regimens offered as standard
therapy in many units and this may explain our excel-
lent baseline LVMI. Although daily hemodialysis may
improve LVMI, it may also increase the burden of dialy-
sis for patients. With daily hemodialysis, the preparation
and clean up time and the cost of consumables is
doubled. Australia and New Zealand data shows a drift
away from the use of daily hemodialysis regimens, with
alternate daily NHD being the most popular and sus-
tainable novel hemodialysis regimen [1]. Our data sug-
gest that a 3.5-5 sessions weekly standard hours regimen
may be sufficient to maintain normal LVMI in most
patients. Regular echocardiographic surveillance may
help identify a subset of patients with deteriorating LV
parameters who may benefit from a trial of daily
hemodialysis.
We note that in our study cardiac diastolic dysfunc-
tion and vascular structure and function parameters
were significantly deranged at baseline in our population
and did not improve with conversion to NHD. Conver-
sion to alternate nightly NHD, which increased session
.
4
.
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p=0.26
n=52
Figure 3 Change in Carotid Intima Media Thickness with Conversion to NHD. NHD = Nocturnal hemodialysis.
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Page 9 of 15duration but not frequency, did not improve LVH even
in the subset of patients with high baseline LVMI.
Therefore, an alternate explanation for the lack of
improvement in cardiovascular parameters in our study
may be inferior control of interdialytic weight gains
(IDWG) and uremic toxins compared with the daily
hemodialysis regimens or RTx. IDWG increased with
conversion to alternate nightly NHD and may have
negated any improvement associated with better control
of other uremia toxins.
There is increasing literature supporting the hypothesis
that all increased intensity hemodialysis regimens may not
be associated with equal benefits to measures of cardiovas-
cular structure and function. Both the FHN Trial group
studies [47] and 1 published small, non-randomized study
comparing alternate daily extended hours hemodialysis (n
= 17) with short daily (n = 8) and standard conventional
hemodialysis (n = 19)[64] have suggested that improve-
ments in LVMass may be greater with short daily hemo-
dialysis regimens compared to NHD. Possible reasons for
this have not been adequately elucidated. It could be pos-
tulated that increasing session frequency maintains low
IDWG. Prolongation of session duration may prolong the
unfavorable hemodynamic changes that occur during
hemodialysis, thus negatively effecting myocardial perfu-
sion. In our study, only a minority of patients changed fre-
quency of dialysis. Statistical adjustment for reduction in
dialysis frequency when converting to NHD did not alter
our results. More studies designed to examine the differ-
ent effects of increasing session frequency as opposed to
duration are needed to clarify these issues.
Previous studies in ESKD have found complex and
inconsistent associations between proposed risk factors
and cardiovascular disease [65,66]. Randomized con-
trolled trials in ESKD have failed to show benefit from
interventions correcting risk factors including anemia
[67,68], dyslipidemia [69,70], hypertension, hyperhomo-
cysteinemia and hyperphosphatemia [71]. In our study,
conversion to NHD resulted in improved calcium, phos-
phate and PTH and a trend towards improved BP.
Changes in markers of inflammation, iron stores and
bone mineral metabolism were only weakly associated
with changes in cardiovascular structure and function in
this study. Our results highlight how poorly we under-
stand the pathogenesis of vascular disease in ESKD and
the need to explore novel risk factors which better
explain, and provide therapeutic targets to reduce cardi-
ovascular morbidity and mortality.
1
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Figure 4 Change in Total Arterial Compliance with Conversion to NHD. NHD = Nocturnal hemodialysis.
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Figure 5 Change in Augmentation Index with Conversion to NHD. NHD = Nocturnal hemodialysis.
Table 5 Changes in Vascular Risk Factor Profiles with conversion from SHD to NHD
Cardiac Risk Factor
Parameter
NHD (n = 41)
Baseline Follow-up p value
Total Cholesterol (mmol/L) 4.4 ± 0.9 4.3 ± 0.8 0.8
Triglycerides (mmol/L) 1.6 (1.1-2.7) 1.1 (0.9-1.7) 0.08
LDL Cholesterol (mmol/L) 2.2 ± 0.8 2.1 ± 0.7 0.7
HDL Cholesterol (mmol/L) 1.5 ± 0.7 1.3 ± 0.4 0.08
Lipoprotein a (mg/L) 150 (90-260) 150 (80-278) 0.8
Systolic Blood Pressure (mmHg) 148 ± 20 141 ± 19 0.06
Diastolic Blood Pressure (mmHg) 83 ± 15 78 ± 13 0.01
Haemoglobin (g/L) 112 ± 12 114 ± 13 0.5
Ferritin (mcg/L) 209 (108-361) 253 (93-345) 0.5
C Reactive Protein (mg/L) 7(5-11) 6 (5-13) 0.6
Albumin (g/L) 42 ± 3 43 ± 4 0.2
Calcium (mmol/L) 2.39 ± 0.30 2.48 ± 0.18 0.02
Phosphate (mmol/L) 1.93 ± 0.55 1.47 ± 0.35 < 0.0001
Calcium Phosphate Product (mmol
2/L
2) 4.61 ± 1.4 3.66 ± 0.86 < 0.0001
Parathyroid Hormone (pmol/L) 290 (140-471) 160 (62-290) 0.03
Homocysteine (mcmol/L) 23 ± 6 22 ± 6 0.5
NHD = Nocturnal hemodialysis; LDL = Low density lipoprotein; HDL = High density lipoprotein
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Page 11 of 15This study is the first to examine the effects of
extended hours hemodialysis on oxidative stress. The
procedure of hemodialysis has been postulated to
increase oxidative stress through contact with bio-
incompatible dialysis equipment and contaminated dia-
lysis water, microhemolysis, alterations in lipid meta-
bolism during heparin exposure and removal of
antioxidants during dialysis [72]. Therefore it is possi-
ble that extended hours HD increases duration of
exposure to these proinflammatory and oxidant stres-
sors compared to conventional HD regimens. Contrary
to this hypothesis, we documented attenuation of the
increase in MDA during dialysis and no consistent
increase in antioxidant enzyme activities. This suggests
that, interestingly, there may be a reduction in lipid
peroxidation during NHD compared to SHD. Inflam-
matory markers including CRP and WCC did not
change with conversion to NHD. We documented an
increase in predialysis RBC-CAT and a decrease in
RBC-GPX with conversion to NHD. The increase in
CAT, an antioxidant enzyme, may have caused the
decrease in GPX, as both enzymes compete to convert
peroxides to less oxidizing compounds. Predialysis
MDA, a breakdown product of oxidized lipids and
marker of oxidative stress [73] remained stable. It
seems likely that interdialytic oxidative stress remained
stable with conversion to NHD.
Vitamins C and E have been identified as important
plasma antioxidants which may be lost in increased
amounts during extended hours HD. We did not mea-
sure serum vitamin C or E levels, although vitamin C
was routinely replaced in all patients. Vitamin C defi-
ciency has been documented in extended hours dialysis
patients where supplementation has not been routine
[74]. This may have contributed to our failure to show
more dramatic improvements in oxidative stress in our
Table 6 Oxidative Stress Changes with Conversion to NHD
Variable Pre dialysis Post Dialysis % Change with Dialysis
MDA (MicroM)
Baseline 16.13+/-3.39 18.1+/-3.74 3.3 (-3.8-27.6)
3 Months 16.50+/-3.19 16.24+/-2.51 -0.66(-8.70-12.41)
6 Months 16.33+/-2.88 16.4+/-2.94 -0.22 (-6.29-5.86)
P value 0.43, 0.71 0.015, 0.018 0.01, 0.005
RBC CAT (U/mgHb)
Baseline 2.97+/-0.86 3.04+/-0.91 2.7+/-12.5
3 Months 3.05+/-0.85 3.21+/-0.82 6.42+/-9.64
6 Months 3.18+/-0.87 3.32+/-0.83 5.47+/-10.80
P Value 0.18, 0.02 0.007, 0.002 0.25, 0.40
RBC GPX (U/gHb)
Baseline 97.2 (40.1-113.4) 99.5 (41.3-112.0) 1.53+/-7.16
3 Months 83.4 (37.9-104.7) 81.1 (37.9-108.6) 3.78+/-10.4
6 Months 70.4 (37.2-95.0) 69.4 (36.0-92.9) -0.10+/-11.3
P Value 0.0001, 0.0003 0.002, 0.0001 0.37, 0.53
Plasma GPX (U/mL)
Baseline 0.030+/-0.008 0.034+/-0.011 12.8+/-11.1
3 Months 0.032+/-0.009 0.035+/-0.011 6.9+/-11.8
6 Months 0.031+/-0.01 0.034+/-0.012 8.3+/-11.6
P Value 0.04, 0.35 0.79, 0.86 0.02, 0.13
RBC SOD (U/mgHb)
Baseline 5.75+/-1.70 6.11+/-1.61 5.69+/-20.83
3 Months 6.32+/-2.30 6.02+/-1.58 -3.41+/-18.0
6 Months 5.87+/-1.63 5.72+/-1.76 4.00+/-30.74
P Value 0.29, 1.0 0.58, 0.33 0.08, 0.29
TAS
Baseline 2.39+/-0.13 2.30+/-0.16 -4.06+/-4.47
3 Months 2.41+/-0.12 2.30+/-0.12 -4.69+/-2.89
6 Months 2.38+/-0.12 2.27+/-0.12 -4.55+/-3.21
P Value 0.54, 0.50 0.95, 0.33 0.64, 0.64
MDA = Plasma malonyldialdehyde; RBC = Red blood cell; CAT = Catalase; GPX = Glutathione peroxidase; SOD = Superoxide dismutase; TAS = Total antioxidant
status
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Page 12 of 15cohort. Further work is needed to confirm vitamin
replacement requirements in NHD.
Strengths and Weaknesses
This is the largest trial examining the effects of increas-
ing dialysis duration on multiple measures of endothelial
function and arterial wall thickness and stiffness and it
is the only study examining cardiac diastolic function
and oxidative stress markers. Echocardiograms and vas-
cular ultrasound studies were all performed and inter-
preted in one experienced laboratory. Patients were all
managed in one unit with uniform policies and proce-
dures. We performed multivariable analyses to adjust
for known confounders. We were powered to detect
clinically significant changes in LVMI, BAR, TAC and
CIMT.
However, our conclusions are limited by the non ran-
domized study design. The baseline dialysis regimen was
not a thrice weekly regimen as is standard in most facil-
i t i e sa n dm a yh a v eb e e nr e s p o n s i b l ef o rt h em o r en o r -
mal baseline LVMI in our study. It could be postulated
that the observation periods used in our, and other stu-
dies have been too short to allow cardiovascular remo-
deling. 2Dimensional echocardiography is less precise
and is more reliant on derived rather than directly mea-
sured values compared to cardiac magnetic resonance
imaging for assessing LVMI [75]. Furthermore, the gen-
erally poor attendance at follow up study visits may
have been a source of bias in this study. Approximately
1/3 of patients did not have follow-up studies com-
pleted. Despite these draw backs, we feel it has merit to
assist with hypothesis generation, power calculations for
randomized controlled trials and to guide clinical prac-
tice whilst definitive studies are conducted.
Conclusion
Conversion to an alternate nightly home hemodialysis
regimen, which only increased dialysis duration and not
frequency, did not result in a significant improvement in
cardiovascular structure and function. Continuing sub-
optimal control of uremic toxin levels, BP and fluid bal-
ance with alternate daily hemodialysis compared to daily
hemodialysis or RTx may be a possible explanation. The
relatively normal LVMI at baseline in our population
also likely contributed to our failure to show improve-
ment in this parameter. A wide range of traditional and
novel cardiovascular risk factors did not strongly corre-
late with cardiovascular structure and function
parameters.
This study adds to the increasing uncertainty in the
published literature about the nature of improvement in
cardiovascular parameters with conversion to intensive
hemodialysis regimens. More work is needed to better
understand the exact mechanisms driving cardiovascular
dysfunction in ESKD and how we might prevent pro-
gression or reverse existing disease. Future randomized
controlled trials will be important to determine whether
increases in dialysis session duration, frequency or both
are most beneficial for improving and slowing the pro-
gression of cardiovascular disease whilst minimizing
costs and the impact of dialysis on quality of life.
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